TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Intercure ( (IL:INCR) ) just unveiled an announcement.
InterCure Ltd. announced its FY2024 results and Q1 2025 update, reporting a revenue of NIS 239 million and an Adjusted EBITDA of NIS 24 million for 2024. The company’s operations were impacted by damages to its southern facility due to a terrorist attack on October 7, 2023, and the ongoing war in Gaza. Despite these challenges, InterCure received partial compensation from Israeli authorities and expects further payments. The company is expanding its strategic partnership with Cookies™ into Germany and is restoring its southern facility to resume profitable growth. For Q1 2025, InterCure projects a strong start with expected sequential growth of over 25% and plans to expand its international operations.
More about Intercure
InterCure, operating under the name Canndoc, is a leading cannabis company outside North America. It is Israel’s largest licensed cannabis producer, offering GMP-certified and pharmaceutical-grade medical cannabis products. The company utilizes a vertically integrated ‘seed-to-sale’ model and has a strong distribution network and international partnerships, positioning it as a leader in the global cannabis market.
YTD Price Performance: -0.38%
Average Trading Volume: 22,141
Technical Sentiment Signal: Buy
Current Market Cap: $74.18M
See more insights into INCR stock on TipRanks’ Stock Analysis page.